Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Black Rock Coffee Bar Fourth Quarter 2025 Earnings Call - Same-store sales and margins accelerated, fueling aggressive expansion
Black Rock closed 2025 with clear momentum: 10.1% full-year same-store sales, 25% revenue growth, and a sharp expansion in profitability that left adjusted EBITDA up 36% for the year and 52% in the fo...
- Revenue and profit momentum: 2025 revenue $200.3 million, up 24.5%, adjusted EBITDA $27.5 million, up 36.2%; Q4 revenue $53.6 million, up 25.3%, Q4 adjusted EBITDA up 52.4% year-over-year.
- Same-store sales strength: 2025 full-year same-store sales +10.1%; Q4 same-store sales +9.3%, and two-year comps roughly +18.8%.
- Store economics improved: store-level profit margin expanded to ~29.2% for the year and 29.4% in Q4, a 130 basis point improvement year-over-year for the full year and 230 basis points in Q4.
- +12 more takeaways
Accel Entertainment Fourth Quarter 2025 Earnings Call - Record revenue and EBITDA, Chicago VGT rollout is the next big lever
Accel closed 2025 with all-time highs in revenue and adjusted EBITDA, while keeping a conservative balance sheet and a clear playbook for growth. Q4 revenue rose 7.5% to $341 million and adjusted EBIT...
- Q4 2025 revenue $341 million, up 7.5% year over year, highest Q4 in company history.
- Q4 adjusted EBITDA $56 million, up 19% year over year, showing margin expansion and operating leverage.
- Full year 2025 revenue above $1.3 billion, adjusted EBITDA $210 million, net income $51 million, EPS $0.61 basic, $0.60 diluted.
- +12 more takeaways
STAAR Surgical Company Fourth Quarter 2025 Earnings Call - Inventory Reset and Swiss-Made EVO+ Position STAAR for 2026 Profitability
STAAR closed a turbulent 2025 with stabilized distributor inventories in China, a sharper cost base, and early commercial production from its Nidau, Switzerland facility aimed at EVO+ demand. Q4 net s...
- Interim leadership in place: Warren Foust and Deborah Andrews appointed Co-CEOs (interim) effective February 1, with Egon Zehnder engaged to search for a permanent CEO.
- Q4 top-line: total net sales $57.8M vs $49.0M a year ago; China net sales $17.5M (Q4 2024: $7.8M).
- Distributor inventory reset in China was deliberate: STAAR paused shipments to normalize channel inventory after elevated levels in 2024, including consumption of a $27.5M December 2024 China shipment during FY2025.
- +13 more takeaways
Ascent Industries Co. Q4 2025 Earnings Call - Structural shift to specialty chemicals drives ~1,000 bps gross margin expansion and $10M+ commercial win
Ascent closed 2025 as a leaner, debt-free specialty chemicals company after exiting legacy tubular assets and the Monell site, and it points to durable margin gains rather than cyclical luck. On a ful...
- Company repositioned into a pure-play specialty chemical platform, permanently exiting legacy tubular assets and the Monell facility.
- Full-year gross margin expanded nearly 1,000 basis points year-over-year, with gross profit up 61% for 2025.
- Adjusted EBITDA improved by about $4.1 million year-over-year for the full year, despite roughly 7% lower revenue versus prior year.
- +14 more takeaways
Cricut Q4 2025 Earnings Call - Profit Up, Revenue Flat as Cricut Bets Big on Bundles and AI
Cricut closed 2025 profitable and cash-generative, but topline momentum is missing. Full-year revenue slipped less than 1% to $708.8 million and Q4 sales fell 3% to $203.6 million, even as net income ...
- Revenue stalled, profits did not. Full-year revenue was $708.8 million, down under 1% year-over-year, while net income rose 22% to $76.7 million.
- Q4 soft patch. Q4 revenue was $203.6 million, down 3% year-over-year, with Q4 net income of $7.8 million, or $0.04 per diluted share.
- Platform is the engine. Platform revenue grew 5% for the year, paid subscribers rose to 3.09 million (up 132,000, +4%), and ARPU increased 5% to $55.77.
- +14 more takeaways
Latham Group, Inc. Q4 and Full Year 2025 Earnings Call - Fiberglass adoption drives outperformance and margin expansion
Latham closed 2025 by outpacing a weak U.S. in-ground pool market, driven by accelerating Fiberglass adoption, auto cover momentum, and margin gains from lean manufacturing and value engineering. Mana...
- Q4 2025 net sales were $100 million, up 15% year-over-year, with organic growth of 14% for the quarter.
- Full-year 2025 net sales were $546 million, up 7% versus $509 million in 2024, achieved while U.S. in-ground pool starts were estimated down low- to mid-single digits.
- Fiberglass pools now represent 76.5% of Latham’s in-ground pool sales in 2025, and Latham’s Fiberglass sales grew approximately 2.5% year-over-year.
- +17 more takeaways
Superior Group of Companies Q4 2025 Earnings Call - Back-end weighted growth, margin lift and AI-driven contact center pivot
Superior posted a muted top line but a noticeable bottom-line recovery in Q4 2025. Consolidated revenue was $147 million, up 1% year-over-year and up 6% sequentially, while EBITDA rose to $8.6 million...
- Consolidated revenue was $147.0 million in Q4 2025, up 1% year-over-year and up 6% sequentially, confirming management’s back-end weighted cadence thesis.
- EBITDA rose to $8.6 million from $7.3 million a year earlier, a 19% increase, and EBITDA margin expanded 90 basis points to 5.9%.
- Diluted EPS nearly doubled to $0.23 in Q4 2025, up from $0.13 in the year-ago quarter.
- +15 more takeaways
Cryoport Q4 & FY2025 Earnings Call - Spring-loaded clinical pipeline sets up commercial revenue surge
Cryoport closed 2025 with a clean beat and a forward-looking posture. Continuing-operations revenue was $176.2 million, above prior guidance, driven by a 29% jump in commercial cell and gene therapy r...
- Continuing-operations revenue for FY2025 was $176.2 million, above the high end of prior guidance.
- Full-year commercial cell and gene therapy revenue rose 29% year-over-year to a record $33.4 million, now representing about 20% of total revenue.
- Clinical trial revenue increased 14% year-over-year to $47.1 million; Cryoport supported a record 760 clinical trials and 20 commercial therapies at year end.
- +11 more takeaways
Evolus Q4 and Full Year 2025 Earnings Call - Portfolio Rebate and Evolysse Launch Set Stage for 2026 Profitability
Evolus closed 2025 with momentum and a clear pivot: double-digit top-line growth, tighter cost discipline, and an explicit plan to use a portfolio rebate and product rollouts to push accounts deeper i...
- Top-line and product mix: Q4 2025 global net revenue was $90.3 million, with full-year 2025 revenue of $297.2 million, up 12% year-over-year and marking six consecutive years of double-digit growth.
- Jeuveau strength: Jeuveau accounted for $83.1 million of Q4 revenue, and management says Jeuveau holds roughly 14% U.S. toxin market share, with continued unit share gains even in a soft procedural environment.
- Evolysse early traction: Evolysse generated $7.2 million in Q4 revenue, more than 3,000 purchasing accounts to date, and management plans a broader sampling and experience program in Q2 2026 to accelerate adoption.
- +13 more takeaways
Arcturus Therapeutics Q4 2025 Earnings Call - Kicking off a 12-week CF Phase 2 as OTC moves to Type C regulatory clarity
Arcturus is narrowing its focus and putting real weight behind two rare disease programs. The company will initiate a 12-week Phase 2 study of ARCT-032 for cystic fibrosis in H1 2026, starting the coh...
- Arcturus will initiate dosing for a 12-week Phase 2 study of ARCT-032 (CF mRNA therapeutic) in H1 2026, enrolling up to 20 Class 1 CF patients across U.S. and international sites.
- The fourth cohort will start at 10 mg with the protocol preserving flexibility to escalate to 15 mg if needed; safety and tolerability were observed at 15 mg in prior cohorts.
- Study design upgrades aim to tighten baseline stability and improve signal detection, including requiring reproducible baseline spirometry before enrollment.
- +11 more takeaways